SG11202002993UA - Novel gamma delta t-cell receptor and its ligand - Google Patents

Novel gamma delta t-cell receptor and its ligand

Info

Publication number
SG11202002993UA
SG11202002993UA SG11202002993UA SG11202002993UA SG11202002993UA SG 11202002993U A SG11202002993U A SG 11202002993UA SG 11202002993U A SG11202002993U A SG 11202002993UA SG 11202002993U A SG11202002993U A SG 11202002993UA SG 11202002993U A SG11202002993U A SG 11202002993UA
Authority
SG
Singapore
Prior art keywords
ligand
cell receptor
gamma delta
novel gamma
novel
Prior art date
Application number
SG11202002993UA
Inventor
Andrew Sewell
Garry Dolton
Original Assignee
Univ College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ College Cardiff Consultants Ltd filed Critical Univ College Cardiff Consultants Ltd
Publication of SG11202002993UA publication Critical patent/SG11202002993UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202002993UA 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand SG11202002993UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1719169.3A GB201719169D0 (en) 2017-11-20 2017-11-20 Novel T-cell receptor and ligand
PCT/GB2018/053321 WO2019097244A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand

Publications (1)

Publication Number Publication Date
SG11202002993UA true SG11202002993UA (en) 2020-06-29

Family

ID=60805814

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002993UA SG11202002993UA (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand

Country Status (15)

Country Link
US (1) US11850264B2 (en)
EP (1) EP3713954A1 (en)
JP (1) JP2021505190A (en)
KR (1) KR20200085776A (en)
CN (1) CN111372944A (en)
AU (1) AU2018369698A1 (en)
BR (1) BR112020007469A2 (en)
CA (1) CA3079156A1 (en)
EA (1) EA202091276A1 (en)
GB (1) GB201719169D0 (en)
IL (1) IL274482A (en)
MX (1) MX2020005200A (en)
SG (1) SG11202002993UA (en)
WO (1) WO2019097244A1 (en)
ZA (1) ZA202002417B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4059955A1 (en) 2021-03-19 2022-09-21 Medizinische Hochschule Hannover Hla-dr-specific gamma delta tcr constructs and use thereof
WO2023148494A1 (en) 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
WO1996013593A2 (en) * 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
ID28040A (en) 1998-05-19 2001-05-03 Avidex Ltd T cell receptor that can dissolve
WO2002087306A2 (en) * 2001-05-01 2002-11-07 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
ATE515189T1 (en) * 2001-12-10 2011-07-15 California Inst Of Techn METHOD FOR PRODUCING ANTIGEN-SPECIFIC LYMPHOCYTES
JP2007528712A (en) * 2003-07-10 2007-10-18 セノミックス、インコーポレイテッド Use of phenamyl to improve the efficacy of ENaC synergists in improved electrophysiological assays using human ENaC expressing oocytes and assays using membrane potential reporter dyes
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
AU2015216875B2 (en) * 2014-02-14 2021-02-25 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
PL3119807T3 (en) * 2014-03-19 2019-09-30 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
TW201623333A (en) 2014-05-13 2016-07-01 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
AU2015295349B2 (en) 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
SG11201707540QA (en) * 2015-03-16 2017-10-30 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Also Published As

Publication number Publication date
KR20200085776A (en) 2020-07-15
US20200316124A1 (en) 2020-10-08
AU2018369698A1 (en) 2020-04-30
WO2019097244A1 (en) 2019-05-23
ZA202002417B (en) 2021-07-28
CN111372944A (en) 2020-07-03
EA202091276A1 (en) 2020-09-04
MX2020005200A (en) 2020-08-20
US11850264B2 (en) 2023-12-26
BR112020007469A2 (en) 2020-11-03
IL274482A (en) 2020-06-30
EP3713954A1 (en) 2020-09-30
CA3079156A1 (en) 2019-05-23
GB201719169D0 (en) 2018-01-03
JP2021505190A (en) 2021-02-18

Similar Documents

Publication Publication Date Title
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
IL274025A (en) Novel t-cell receptor
IL264514A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL286107A (en) Spiro-lactam nmda receptor modulators and usesthereof
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3490994C0 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11202002528SA (en) Radioactive drug
SG11202103609YA (en) T-cell receptors and uses thereof
HK1258886A1 (en) T-cell receptor and uses thereof
ZAA201800549S (en) Tablets
EP3512537C0 (en) T-cell immunotherapy
EP3517904A4 (en) Hopper and combination weighing device
IL272808B (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
IL274482A (en) Novel gamma delta t-cell receptor and its ligand
SG11202003305UA (en) Boron structure and boron powder
EP3598085A4 (en) Combination weighing device
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
PL3654914T3 (en) Drug mixing device
GB201700404D0 (en) Compounds and composistions
EP3540386A4 (en) Combination weighing device
GB201705960D0 (en) Novel ligand and use thereof
SE1850580A1 (en) Hoist device
GB201706266D0 (en) Intrinsically safe screen means
GB201719948D0 (en) Ring binders/tramperline binders any size and any size extra